MA28550B1 - Composes et procedes permettant de traiter la dyslipidemie - Google Patents

Composes et procedes permettant de traiter la dyslipidemie

Info

Publication number
MA28550B1
MA28550B1 MA29410A MA29410A MA28550B1 MA 28550 B1 MA28550 B1 MA 28550B1 MA 29410 A MA29410 A MA 29410A MA 29410 A MA29410 A MA 29410A MA 28550 B1 MA28550 B1 MA 28550B1
Authority
MA
Morocco
Prior art keywords
methods
compounds
treating dyslipidemia
dyslipidemia
treating
Prior art date
Application number
MA29410A
Other languages
English (en)
French (fr)
Inventor
Michael Gregory Bell
Guoqing Cao
Ana Maria Escribano
Maria Carmen Fernandez
Peter Ambrose Lander
Nathan Bryan Mantlo
De La Nava Eva Maria Martin
Herranz Ana Isabel Mateo
Daniel Ray Mayhugh
Xiaodong Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA28550B1 publication Critical patent/MA28550B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA29410A 2004-03-26 2006-10-23 Composes et procedes permettant de traiter la dyslipidemie MA28550B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55713404P 2004-03-26 2004-03-26
US62116204P 2004-10-22 2004-10-22

Publications (1)

Publication Number Publication Date
MA28550B1 true MA28550B1 (fr) 2007-04-03

Family

ID=34963426

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29410A MA28550B1 (fr) 2004-03-26 2006-10-23 Composes et procedes permettant de traiter la dyslipidemie

Country Status (21)

Country Link
US (2) US7470705B2 (enExample)
EP (2) EP1735320B1 (enExample)
JP (1) JP2007530550A (enExample)
KR (1) KR20070007112A (enExample)
AT (2) ATE433984T1 (enExample)
AU (1) AU2005230915A1 (enExample)
BR (1) BRPI0508966A (enExample)
CA (1) CA2557010A1 (enExample)
CY (1) CY1110398T1 (enExample)
DE (2) DE602005014955D1 (enExample)
DK (1) DK1732933T3 (enExample)
EA (1) EA200601785A1 (enExample)
EC (1) ECSP066886A (enExample)
ES (2) ES2308477T3 (enExample)
IL (1) IL177962A0 (enExample)
MA (1) MA28550B1 (enExample)
NO (1) NO20064763L (enExample)
PL (1) PL1732933T3 (enExample)
PT (1) PT1732933E (enExample)
SI (1) SI1732933T1 (enExample)
WO (2) WO2005097805A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
ATE433984T1 (de) * 2004-03-26 2009-07-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
EA200700119A1 (ru) 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
ES2644450T3 (es) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
SI2207775T1 (sl) 2007-11-05 2012-05-31 Novartis Ag benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza
EP2404901B1 (en) 2007-12-03 2013-05-22 Novartis AG 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
JP2011506441A (ja) * 2007-12-12 2011-03-03 アムジエン・インコーポレーテツド グリシン輸送体−１阻害薬
JP5586585B2 (ja) * 2009-03-27 2014-09-10 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
KR20120036850A (ko) 2009-05-15 2012-04-18 노파르티스 아게 알도스테론 신타제 억제제로서의 벤족사졸론 유도체
MX2011012198A (es) 2009-05-15 2011-12-08 Novartis Ag Aril-piridinas como inhibidoras de sintasa de aldosterona.
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
JP5964247B2 (ja) * 2010-02-24 2016-08-03 レリプサ， インコーポレイテッド 胆汁酸捕捉剤として使用するためのポリイミダゾール
NZ603453A (en) 2010-05-06 2014-12-24 Alphacore Pharma Llc Delivery of cholesteryl ester to steroidogenic tissues
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
TWI627167B (zh) 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
EP2760864B1 (en) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
US20140303198A1 (en) 2011-11-29 2014-10-09 Kowa Company, Ltd. Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EP2956464B1 (en) 2013-02-14 2018-03-28 Novartis AG Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1515540A (en) * 1975-12-16 1978-06-28 Labaz 4-amino-trans-decahydroquinoline derivatives
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
WO1998035967A2 (en) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
EP1466904A4 (en) * 2001-12-28 2005-12-14 Takeda Pharmaceutical BIARYL CONNECTION AND ITS USE
JP2005522424A (ja) 2002-02-01 2005-07-28 ファイザー・プロダクツ・インク コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
SK2332004A3 (en) 2002-08-30 2004-12-01 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
EP1556047A4 (en) * 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
ATE433984T1 (de) 2004-03-26 2009-07-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
EA200700119A1 (ru) 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии

Also Published As

Publication number Publication date
NO20064763L (no) 2006-11-22
KR20070007112A (ko) 2007-01-12
EP1735320A1 (en) 2006-12-27
BRPI0508966A (pt) 2007-08-21
DE602005008416D1 (de) 2008-09-04
US7470705B2 (en) 2008-12-30
DE602005014955D1 (de) 2009-07-30
AU2005230915A1 (en) 2005-10-20
EA200601785A1 (ru) 2007-02-27
CA2557010A1 (en) 2005-10-20
JP2007530550A (ja) 2007-11-01
IL177962A0 (en) 2006-12-31
DK1732933T3 (da) 2008-10-27
PT1732933E (pt) 2008-10-20
US20070208003A1 (en) 2007-09-06
EP1732933A1 (en) 2006-12-20
ES2308477T3 (es) 2008-12-01
ATE433984T1 (de) 2009-07-15
WO2005097805A1 (en) 2005-10-20
ECSP066886A (es) 2006-11-24
SI1732933T1 (sl) 2008-10-31
CY1110398T1 (el) 2015-04-29
ES2326326T3 (es) 2009-10-07
ATE402180T1 (de) 2008-08-15
EP1732933B1 (en) 2008-07-23
WO2005097806A1 (en) 2005-10-20
US20070173526A1 (en) 2007-07-26
PL1732933T3 (pl) 2008-12-31
EP1735320B1 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
MA28550B1 (fr) Composes et procedes permettant de traiter la dyslipidemie
ATE433447T1 (de) Pyrimiidinverbindungen
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
SE0302811D0 (sv) Novel compounds
TW200617009A (en) Organic compounds
TW200626579A (en) Inhibitors of the interaction between MDM2 and p53
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
TW200640859A (en) Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists
ATE422198T1 (de) Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten
GEP20115201B (en) Cinnamoyl-piperazine derivatives and their use as par- i antagonists
SE0303541D0 (sv) New compounds
TW200510427A (en) Novel fused heterocycles and uses thereof
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
EA200801199A1 (ru) Ингибиторы киназы
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
MA28268A1 (fr) Composes et techniques de traitement de la dyslipidemie
SE0303090D0 (sv) Novel compounds
TW200740781A (en) Novel compounds
NO20063293L (no) Farmasoytiske forbindelser
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase
TW200621260A (en) Selected fused heterocyclics and uses thereof
FR2894578B1 (fr) Derives heterocycliques, leur preparation et leur application en therapeutique.